Substudy-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate [SUBSTUDY of 700028860]
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms MTR-IR
- Sponsors Bristol-Myers Squibb
- 02 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jun 2013 New trial record